Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» RNAi
RNAi
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Sun, 10/18/20 - 08:32 pm
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Endpoints
Thu, 10/8/20 - 10:59 am
Takeda
RNAi
Arrowhead Pharmaceuticals
Rare Diseases
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Fierce Biotech
Wed, 09/30/20 - 10:35 am
Alnylam
clinical trials
lumasiran
RNAi
PH1
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Xconomy
Wed, 09/16/20 - 07:28 pm
Arrowhead Pharmaceuticals
clinical trials
liver disease
RNAi
ARO-AAT
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
BioPharma Dive
Sat, 08/29/20 - 11:42 pm
Arrowhead Pharmaceuticals
JNJ
clinical trials
RNAi
hepatitis B
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
Fierce Biotech
Fri, 08/28/20 - 10:47 am
JNJ
RNAi
JNJ-3989
hepatitis B
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EP Vantage
Fri, 08/28/20 - 10:34 am
EASL
RNAi
hepatitis B
Assembly Biosciences
Abrutus
JNJ
GSK
Vir Biotechnology
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Endpoints
Wed, 08/19/20 - 11:45 pm
Regeneron
inclisiran
RNAi
Novartis
New England Journal of Medicine
Bayer helps Harvard spinout Vesigen to $28.5M series A
Fierce Biotech
Wed, 07/22/20 - 10:39 am
Bayer
Vesigen Therapeutics
Harvard
RNAi
MRNA
CRISPR
Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show
Fierce Pharma
Tue, 06/30/20 - 10:51 am
Alnylam
RNAi
Givlaari
acute hepatic porphyria
Dicerna nabs speedy review voucher for leading RNAi drug
Fierce Biotech
Thu, 06/18/20 - 10:36 am
Dicerna
RNAi
priority review
nedosiran
Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data
Endpoints
Sun, 06/7/20 - 10:32 pm
Alnylam
clinical trials
RNAi
lumasiran
PH1
Alnylam nabs speedy review, setting up 3rd possible approval in 3 years
Endpoints
Tue, 05/26/20 - 11:12 am
Alnylam
RNAi
FDA
drug approvals
lumasiran
hyperoxaluria
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Fierce Biotech
Mon, 05/4/20 - 10:37 am
Alnylam
Vir Biotechnology
COVID-19
RNAi
clinical trials
Alnylam's vutrisiran gets fast-track treatment at the FDA
Fierce Biotech
Tue, 04/14/20 - 09:44 am
Alnylam
RNAi
FDA
hATTR
vutrisiran
fast track
Blackstone backs Alnylam with up to $2B investment
BioPharma Dive
Mon, 04/13/20 - 09:50 pm
generics
Alnylam
Blackstone
RNAi
Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis
Pharmaceutical Business Review
Mon, 04/13/20 - 10:50 am
Arrowhead Pharmaceuticals
clinical trials
cystic fibrosis
ARO-ENaC
RNAi
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
Endpoints
Mon, 04/6/20 - 10:29 am
Alnylam
Dicerna
John Maraganore
Douglas Fambrough
RNAi
Merck
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Fri, 04/3/20 - 11:15 am
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Pharmaceutical Business Review
Thu, 03/26/20 - 10:22 am
Alnylam
RNAi
Gen
Onpattro
Turkey
hATTR amyloidosis
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »